XRXiaolei Ren

Xiaolei Ren

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaolei Ren has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Zhihong Li

    Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha, China

    8 shared publications
  • Chao Tu

    Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha, China

    6 shared publications
  • Ruiling Xu

    Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China

    6 shared publications
  • Lin Qi

    Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China

    3 shared publications
  • Sai Zhu

    Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China

    3 shared publications
  • Wenchao Zhang

    Department of Orthopedics The Second Xiangya Hospital Central South University Changsha Hunan 410011 P. R. China

    3 shared publications

Latest Publications

  • Open Access

    NCAPD3 promotes osteosarcoma progression by modulating macrophage polarization and tumor cell proliferation

    by Ruiling Xu, Binfeng Liu, Sai Zhu, Lin Qi, Lu Wan, Ruiqi Chen, Lu Wang, Xiaolei Ren, Zhihong Li

    Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents, characterized by aggressive behavior and poor prognosis. Des


  • Open Access

    The emerging role of aptamers in targeted cancer immunotherapy

    by Sai Zhu, Ruiling Xu, Haodong Xu, Yu Wang, Lu Wang, Na He, Hong-Hui Wang, Xiaolei Ren


  • Open Access

    Is physical activity in polluted environments beneficial or detrimental to osteoporosis and osteoarthritis? A prospective cohort study

    by Linghui Xiang, Ruiling Xu, Xiaolei Ren, Zhihong Li, Shiqi Xiang, Irene Xy Wu

    Background: Although physical activity and environmental pollutants may influence the risk of osteoporosis and osteoarthritis, their combined effects remain poorly understood. Therefore, we aimed to evaluate the independent associations of environmental pollutants and physical activity with these risks and to explore their interaction. Methods: We conducted a prospective cohort study of 400949 UK Biobank participants. Environmental pollutants comprised particulate matter (PM 2.5 , PM 10 , and PM 2.5-10 ), nitrogen oxides (NO x , NO 2 , and NO), air pollutant score, and 24-hour noise. Physical activity was classified by intensity (low, moderate, and high) and by type [walking for pleasure, strenuous sports, light DIY (do it yourself) heavy DIY and other sports]. We used multivariable Cox models to estimate the independent associations of each exposure with disease risk. Interaction analyses between pollutants and physical activity were then performed on both the additive scale (relative excess risk due to interaction) and the multiplicative scale (interaction term P value). Results: During follow-up, 9667 and 46 782 participants developed osteoporosis and osteoarthritis, respectively. Air pollutants were generally associated with an increased risk of osteoporosis and osteoarthritis. Physical activity (regardless of intensity and type) reduced osteoporosis risk, while a high level of physical activity increased osteoarthritis risk. Additionally, strenuous sports increased osteoarthritis risk, while walking for pleasure decreased it. Under most conditions, we observed neither additive nor multiplicative interaction between pollutants and physical activity. Conclusions: Caution is warranted for the increased osteoarthritis risk with high intensity of physical activity. However, effects of physical activity (whether beneficial or harmful) on osteoporosis and osteoarthritis are not markedly altered by pollutants.


  • Top Cited Papers
    Open Access

    A Dual Approach with Organoid and CRISPR Screening Reveals ERCC6 as a Determinant of Cisplatin Resistance in Osteosarcoma

    by Ruiling Xu, Sai Zhu, Wenchao Zhang, Haodong Xu, Chao Tu, Honghui Wang, Lu Wang, Na He, Tang Liu, Xiaoning Guo, et al.

    Osteosarcoma (OS), the most prevalent primary bone malignancy in adolescents, is typically treated with cisplatin‐based chemotherapy. However, the development of cisplatin resistance often leads to relapse or metastasis, significantly impairing therapeutic efficacy. To tackle this issue, patient‐derived osteosarcoma organoids (OSOs) is established that accurately reflect the cellular composition and heterogeneity of the original tumors, as validated by single‐cell RNA sequencing, bulk RNA sequencing, and histopathology analysis. Cisplatin resistance is successfully induced in these OSOs, creating a clinically relevant model for investigating chemoresistance. Utilizing RNA sequencing in cisplatin‐resistance OSOs and CRISPR screening in OS cell line, ERCC6 is identified as a pivotal regulator of cisplatin resistance. Knockdown of ERCC6 markedly enhanced cisplatin sensitivity in vitro and in vivo. Mechanistically, ERCC6 interacts with HNRNPM, influencing the PI3K/AKT signaling pathway and alternative splicing of pre‐mRNA for BAX. Notably, the knockdown of ERCC6 and HNRNPM increased expression of full‐length BAX and reduced skipping of exon 2, thus promoting apoptosis. This exon skipping in BAX results in a frameshift and introduces a premature stop codon (TGA) within the BH3 domain. These findings underscore the utility of OSOs in elucidating resistance mechanisms and highlight ERCC6 and HNRNPM as potential therapeutic targets.


  • Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma

    by Wenchao Zhang, Lin Qi, Haodong Xu, Chi Yin, Zhuowen Yu, Ruiling Xu, Chengyao Feng, Xiaolei Ren, Chao Tu, Zhihong Li

    Osteosarcoma is a common primary malignant bone tumor in children and young adults, with limited progress in improving survival rates for metastatic or recurrent cases. Kinase inhibitors have emerged as potential treatments for osteosarcoma due to the critical role kinases play in regulating cellular networks. However, single-agent kinase inhibitors often face challenges due to the activation of compensatory oncogenic signaling pathways, which can undermine treatment efficacy. In this study, a combination screening of FDA-approved kinase inhibitors was conducted in osteosarcoma cells. We identified the combination of ALK inhibitor and FLT3 inhibitor as a potent kinase-based therapeutic strategy for osteosarcoma. Our results showed that the combinatorial treatment synergistically suppressed osteosarcoma in cell lines, patient-derived organoids, and xenograft models. Mechanistically, the inhibition of FLT3 significantly promoted the activation of ALK, which subsequently enhanced its downstream PI3K/Akt and MAPK signaling pathways. The combinatorial use of an ALK inhibitor could reverse this process. Thus, our study demonstrates that the cooperative blockade of FLT3 and ALK synergistically suppresses osteosarcoma, providing a potential alternative for its treatment.


  • 3D Models of Sarcomas: The Next-generation Tool for Personalized Medicine

    by Ruiling Xu, Ruiqi Chen, Chao Tu, Xiaofeng Gong, Zhongyue Liu, Lin Mei, Xiaolei Ren, Zhihong Li

    Sarcoma is a complex and heterogeneous cancer that has been difficult to study in vitro. While two-dimensional (2D) cell cultures and mouse models have been the dominant research tools, three-dimensional (3D) culture systems such as organoids have emerged as promising alternatives. In this review, we discuss recent developments in sarcoma organoid culture, with a focus on their potential as tools for drug screening and biobanking. We also highlight the ways in which sarcoma organoids have been used to investigate the mechanisms of gene regulation, drug resistance, metastasis, and immune interactions. Sarcoma organoids have shown to retain characteristics of in vivo biology within an in vitro system, making them a more representative model for sarcoma research. Our review suggests that sarcoma organoids offer a potential path forward for translational research in this field and may provide a platform for developing personalized therapies for sarcoma patients.


  • Open Access

    Integrated Analysis of TME and Hypoxia Identifies a Classifier to Predict Prognosis and Therapeutic Biomarkers in Soft Tissue Sarcomas

    by Ruiling Xu, Lin Qi, Xiaolei Ren, Wenchao Zhang, Chenbei Li, Zhongyue Liu, Chao Tu, Zhihong Li

    Soft tissue sarcoma (STS) is one of the rarest but most aggressive cancer. It is important to note that intratumoral hypoxia and tumor microenvironment (TME) infiltration play a significant role in the growth and therapeutic resistance of STS. The goal of this study was therefore to determine whether linking hypoxia-related parameters to TME cells could provide a more accurate prediction of prognosis and therapeutic response. An analysis of 109 hypoxia-related genes and 64 TME cells was conducted in STS. Hypoxia-TME classifier was constructed based on 6 hypoxia prognostic genes and 8 TME cells. As a result, we evaluated the prognosis, tumor, and immune characteristics, as well as the effectiveness of therapies in Hypoxia-TME-defined subgroups. The Lowplus group showed a better prognosis and therapeutic response than any other subgroup. It is possible to unravel these differences based on immune-related molecules and somatic mutations in tumors. Further validation of Hypoxia-TME was done in an additional cohort of 225 STS patients. Additionally, we identified five key genes through differential analysis and RT-qPCR, namely, ACSM5, WNT7B, CA9, MMP13, and RAC3, which could be targeted for therapy. As a whole, the Hypoxia-TME classifier demonstrated a pretreatment predictive value for prognosis and therapeutic outcome, providing new approaches to therapy strategizing for patients.


  • Open Access

    Prognostic and clinicopathologic significance of circZFR in multiple human cancers

    by Zhongyue Liu, Wenchao Zhang, Chao Tu, Wenyi Li, Lin Qi, Zhiming Zhang, Lu Wan, Zhimin Yang, Xiaolei Ren, Zhihong Li

    Background: Abnormally expressed in diverse cancers, circZFR has been correlated with clinical outcomes of cancer patients. Aim of this meta-analysis was to elucidate the prognostic role of circZFR in multiple human malignancies. Methods: Literature retrieval was conducted by systematically searching on Pubmed, Web of Science, and the Cochrane Library up to December 2nd, 2021. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were pooled to evaluate the association between circZFR expression and overall survival (OS). The reliability of the pooled results was assessed through sensitivity analysis and the publication bias was measured by Begg’s and Egger’s test. Results: A total of seventeen studies comprising 1098 Chinese patients were enrolled in this meta-analysis. Results demonstrated that high circZFR expression was correlated with an unfavorable OS (HR = 2.14, 95% CI 1.74, 2.64). High circZFR expression predicted larger tumor size (OR = 2.79, 95% CI 1.52, 5.12), advanced clinical stage (OR = 3.38, 95% CI 1.49, 7.65), tendentiousness of lymph node metastasis (LNM) (OR = 3.08, 95% CI 2.01, 4.71), and malignant grade (OR = 3.18, 95% CI 1.09, 9.30), but not related to age, gender, and distant metastasis (DM). Conclusions: High circZFR expression was associated with unfavorable OS and clinicopathologic parameters including tumor size, clinical stage, LNM, and histology grade, implicating a promising prognostic factor in cancers.


  • Open Access

    Incidence and Prognosis of Bone Metastasis in Newly Diagnosed Differentiated Thyroid Carcinoma: A SEER Population-Based Study

    by Lin Qi, Wenchao Zhang, Xiaolei Ren, Chaoqian Liu, Chao Tu, Zhihong Li

    Background: Clinical characteristics and sociodemographic of differentiated thyroid carcinoma (DTC) patients with bone metastasis (BM) remain unclear. Methods: Data of patients with newly diagnosed DTC from 2010 to 2016 were retrieved from Surveillance, Epidemiology, and End Results (SEER) database. Incidence trend of BM in patients with DTC was explored by joinpoint regression. Multivariable logistic regression was utilized to figure out predictors of BM at initial presentation of DTC, and was further evaluated by receiver operator characteristics (ROC) analysis. Multivariable Cox regression was applied to reason out factors associated with overall survival and DTC-specific survival.Results: A total of 67,176 patients with DTC were identified from the database, with 0.36% (244/67176) presenting BM at the time of diagnosis. The age-adjusted incidence of BM in DTC was relatively stable during study period with an average annual percentage change (AAPC) of 2.52. Multivariable logistic regression recognized eight factors as predictors of presence of BM among the entire cohort. Multivariable Cox regression indicated multiple metastatic sites, total thyroidectomy and radioisotopes as predictors for survival of patients.Conclusions: The incidence of BM in DTC patients has been stable in recent years. Predictors and prognostic factors of BM in DTC patients were identified in this study.

  • Open Access

    Upregulated expression of LncRNA nicotinamide nucleotide transhydrogenase antisense RNA 1 is correlated with unfavorable clinical outcomes in cancers

    by Chenghao Zhang, Xiaolei Ren, Zhongyue Liu, Chao Tu

    Background: The nicotinamide nucleotide transhydrogenase antisense RNA 1 (NNT-AS1) is a long non-coding RNA aberrantly expressed in human malignancies. We aimed to analyze available data to evaluate the correlation between NNT-AS1 expression and cancer prognosis.Methods: Literature retrieval was performed by systematic searching related databases from inception to April 2, 2020. Studies regarding correlation between NNT-AS1 expression, survival outcomes and clinical characteristics of cancer patients were collected and pooled to calculate the the hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (95% CIs).Results: Ten studies comprising 699 patients were included, all of which were conducted in China according to literature selection criteria. Overexpression of NNT-AS1 had a significant association with unfavorable overall survival (OS) (HR = 2.08, 95% CI: 1.84–2.36,P < 0.001). Stratified analysis showed that tumor type, sample size, follow-up months, and survival analysis approach did not change the predictive value of NNT-AS1 on OS. Furthermore, elevated NNT-AS1 level had significant association with distant metastasis (DM) (OR = 2.45, 95% CI: 1.39–4.30), lymph node metastasis (LNM) (OR = 3.92, 95% CI: 1.35–11.41), TNM stage (OR = 4.25, 95% CI: 1.71–10.56), and vascular invasion (OR = 3.98, 95% CI: 2.06–7.71), but was not associated with age and gender. The TCGA dataset further consistently showed that the NNT-AS1 expression was associated with poor OS and disease-free survival.Conclusions: High expression of NNT-AS1 is associated with unfavorable survival outcomes and poor clinicopathologic characteristics. However, large-cohort data and geographical studies are still needed to further validate the prognostic value of NNT-AS1 in cancers.